Company intelligence / Profile preview

Uvisa Health

Copenhagen, Denmark

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Uvisa Health has completed preclinical studies demonstrating that its light-based therapeutic device can safely and effectively reduce pathogenic microbes while sparing beneficial bacteria. It is now entering its first human clinical trial in Denmark for the treatment of vulvovaginal candidiasis and bacterial vaginosis, aiming for a non-drug therapy option for these common vaginal infections. No human efficacy results published as of September 2025.

Therapeutic areas: Infectious DiseasesWomen's Health
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

Odense University HospitalCopenhagen UniversityDanish Technical University (DTU)Statens Serum InstitutRegion Hovedstaden

Beyond the preview

Go deeper on Uvisa Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Uvisa Health.

Explore the full profile